Imago BioSciences, Inc. (Imago) (NASDAQ: IMGO), a medical stage biopharmaceutical business discovering new medicines for the therapy of myeloproliferative neoplasms (MPNs), has introduced the closing of US$134.four million in gross proceeds from its beforehand introduced preliminary public providing and US$20 million in gross proceeds from its concurrent personal placement.
The preliminary public providing of 8,400,000 shares of frequent inventory at a public providing value of US$16 per share resulted in combination gross proceeds to Imago of US$134.four million, earlier than deducting underwriting reductions, commissions and providing bills. All of the shares within the preliminary public providing had been supplied by Imago.
Latham & Watkins LLP represents Imago BioSciences, Inc. within the providing with a company deal workforce led by Bay Area companions Ben Potter and Rick Kline, with associates Tess Bloom, Taimi Jacobson and Ajay Sundar. Advice was additionally supplied on healthcare and life sciences regulatory issues by Washington, D.C. companion Elizabeth Richards and Bay Area counsel Betty Pang, with Los Angeles affiliate Leia Gu; on profit and compensation issues by Bay Area companion Jay Metz; on mental property issues by Bay Area companion Judith Hasko, with affiliate Stephanie Blij; and on tax issues by Bay Area companion Katharine Moir.